| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Pirfenidone capsules (ETUARY®) pneumoconiosis | Phase 3 | — | Small Molecules | Respiratory System | ||
phase 3 data readout example | Pirfenidone capsules (ETUARY®) pneumoconiosis | Phase 3 | — | Small Molecules | Respiratory System | ||
phase 3 data readout example | Pirfenidone capsules (ETUARY®) pneumoconiosis | Phase 3 | — | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
Gyre Therapeutics, Inc.$6.29
+0.06 (+0.96%)
C 51Pipeline Score Fair Value Pharma · Commercial
Market Cap
587.78 M
EPS
-0.07
P/E Ratio
-
Value Trade
405.56 K
SEC Financials
Q1 2026Dilution Risk
Revenue
22.52 M
R&D Expenses
6.74 M
Operating CF
3.18 M
Total Assets
162.01 M
Total Liabilities
25.03 M
Equity
101.31 M
D/E Ratio
12,345
-11.79 %
Week
-23.48 %
1 Month
-27.77 %
3 Month
-18.33 %
6 Month
-90.75 %
5 Year
-99.96 %
All Time
Cash Data
Cash Position
49.81 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
854.11 K
52 Week Range
5.97 - 11.61
% held by Insiders
81.79 %
% held by Institutions
3.53 %
Enterprise Value
574.47 M
Total Shares
96.94 M
Short %
9.76 %
Float Shares
17.84 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C51
Pipeline Score $989M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.7x
rNPV / MCap Top 79%
Micro Cap (rank 191 of 905)
Percentile RankGyre Therapeutics, Inc. carries a moderate pipeline score (51/100), with $4.9B risk-adjusted pipeline value, led by Coagulation Factor IX variant in Hemophilia B (Phase 2), across $53B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coagulation Factor IX variant Monoclonal antibody | Hemophilia B | Phase 2 | NCT03995784 | 45% | $1.9B | COMPLETED | 6 | - | - | Apr 1, 2020 | - | Aug 8, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Hydronidone | CHB-associated liver fibrosis | Phase 3 | 2025-08-12 | |||
Hydronidone | CHB-associated liver fibrosis | Phase 3 | 2025-08-12 | |||
Hydronidone | CHB-associated liver fibrosis | Phase 3 | 2025-08-12 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GYRE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
GYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GYRE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
GYRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GYREA Fully-Integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory Diseases and Cancer This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Sect
Gyre Therapeutics has recently presented its strategic vision focusing on fibrosis, inflammatory diseases, and cancer, while noting the substantial risks associated with forward-looking statements. The company aims to leverage its operations in China for enhanced drug discovery and development to advance its therapeutic pipeline. Key product candidates include CG923308 and ETUARY, which are currently in various stages of clinical development. However, Gyre also cautions about the challenges related to regulatory processes and competitive market pressures impacting its financial outlook.
Read more →GYREA Fully-integrated Biopharmaceutical Company Focused on Fibrosis, Inflammatory Diseases and Cancer May 2026 This presentation contains "forward-looking statements" within the meaning of the federal securities laws, inclu
Gyre Therapeutics, a biopharmaceutical company, has outlined its strategy and plans focusing on fibrosis, inflammatory diseases, and cancer. The company is leveraging its Chinese operations for drug discovery and development. Gyre's pipeline includes both investigational and marketed products, with a focus on innovative therapeutics such as protein degraders. The presentation also highlights the challenges associated with forward-looking statements and the inherent risks in clinical development.
Read more →GYREGyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
Gyre Therapeutics announced the acceptance of its New Drug Application for F351 (hydronidone) by China's NMPA for treating chronic hepatitis B-induced liver fibrosis. This follows a priority review status granted earlier, marking a significant milestone for Gyre. The drug aims to address a critical medical need for millions of patients in China suffering from HBV-related liver damage.
Read more →GYREGyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F35
Gyre Therapeutics reported its first quarter 2026 financial results, showing a revenue increase to $22.5 million with a net loss of $9.9 million. The company has affirmed its full year revenue guidance between $100.5 and $111.0 million. Notably, they submitted a New Drug Application (NDA) for F351 to treat CHB-associated liver fibrosis and completed the acquisition of Cullgen to expand its pipeline. Furthermore, the first patient has been enrolled in a Phase 2/3 trial of ETUARYTM for radiation-induced lung injury, reflecting ongoing development efforts.
Read more →GYREGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics has successfully acquired Cullgen Inc. in a $300 million all-stock deal, creating a fully integrated biopharmaceutical company with a focus on fibrosis and inflammatory diseases. The combined entity will leverage its commercial asset, ETUARY®, and a robust pipeline including targeted protein degraders. Leadership changes include Dr. Ying Luo as CEO, aiming for global growth and expansion of product development.
Read more →GYREGYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm
Kaskela Law LLC has announced an investigation into Gyre Therapeutics, Inc. due to potential violations of securities laws and breaches of fiduciary duties by the company's officers and directors. This investigation is aimed at determining the legality of recent corporate actions taken by Gyre. Shareholders are encouraged to reach out to the law firm for more information regarding their legal rights concerning this matter.
Read more →GYREGyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
Gyre Therapeutics announced that China's NMPA has granted priority review status to its NDA for Hydronidone (F351), aimed at treating chronic hepatitis B-induced liver fibrosis. This milestone follows a pre-NDA communication meeting and highlights the urgent medical need for effective therapies in this area. The company plans to submit the formal NDA soon.
Read more →GYREGyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Gyre Therapeutics reported a 10% increase in full-year 2025 revenue, reaching $116.6 million. The company anticipates a decline in revenue for 2026, projecting between $100.5 million and $111.0 million. Gyre is advancing its Hydronidone drug towards conditional approval in China and has completed enrollment for a Phase 3 trial on pneumoconiosis. Additionally, Gyre plans to acquire Cullgen to enhance its drug development capabilities.
Read more →GYREGyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Gyre Therapeutics has announced an agreement to acquire Cullgen in an all-stock transaction valued at approximately $300 million. This acquisition aims to enhance Gyre's capabilities in targeted protein degradation and expand its therapeutic pipeline. Following the transaction, Cullgen will operate as a wholly owned subsidiary, with its CEO expected to lead Gyre. The deal is anticipated to close in early Q2 2026, pending regulatory approvals.
Read more →GYREGyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
Gyre Therapeutics announced a successful Pre-NDA meeting with China's CDE regarding Hydronidone, its anti-fibrotic therapy for chronic hepatitis B-associated liver fibrosis. The CDE found existing Phase 3 data supportive for a conditional approval NDA submission. Hydronidone has also been designated as a Breakthrough Therapy, facilitating an expedited review process. The company plans to submit the NDA in the first half of 2026.
Read more →GYREGyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Gyre Therapeutics announced its financial results for Q3 2025, reporting a net income of $5.9 million. The company revised its full-year revenue guidance down to $115-118 million due to delays in the rollout of Etorel® and uncertainties in government procurement. Despite these challenges, Gyre continues to advance its clinical pipeline, including the NDA submission for Hydronidone in China.
Read more →GYREGyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Gyre Therapeutics has announced the completion of patient enrollment in a Phase 3 clinical trial for Pirfenidone capsules, aimed at treating pneumoconiosis. The trial, involving 272 patients across 18 centers in China, will assess the drug's efficacy and safety over 52 weeks. This development highlights the significant unmet medical need for effective therapies targeting this chronic lung disease.
Read more →GYREGyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
Gyre Therapeutics announced positive results from its Phase 3 clinical trial of Hydronidone for treating liver fibrosis in chronic hepatitis B. The findings will be presented at The Liver Meeting® 2025, where the abstract has been recognized as a Poster of Distinction. The meeting is scheduled for November 7-10, 2025, in Washington D.C.
Read more →GYREDeveloping Anti-Fibrotic Therapeutics for Chronic Organ Diseases H.C. Wainwright Global Investment Conference September 2025 Forward Looking Statements 2 This presentation contains "forward-looking statements" within the
Gyre Therapeutics presented at the H.C. Wainwright Global Investment Conference, discussing its forward-looking strategies and plans for anti-fibrotic therapeutics. The company is advancing its products targeting chronic organ diseases, highlighting the encouraging clinical trial results of Hydronidone for liver fibrosis. Gyre maintains a strong market presence in China with its leading product ETUARY for Idiopathic Pulmonary Fibrosis (IPF). The company has also made strategic acquisitions to bolster its offerings in the IPF and liver disease treatment markets.
Read more →GYREGyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. The company focuses on fibrosis-first therapies, particularly for liver fibrosis. The presentation will be available via live webcast and later as a replay on their website.
Read more →GYREGyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics has appointed Dr. Dan Weng to its Board of Directors, effective August 18, 2025. Dr. Weng brings nearly four decades of experience in managing global clinical trials and has held leadership roles in various contract research organizations. His expertise is expected to support Gyre's strategic growth and expansion of its multi-national pipeline.
Read more →GYREGyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update Net income of $1.6 million and $5.3 million for the three and six months ended
Gyre Therapeutics recently released its financial results for Q2 2025, showcasing a net income of $1.6 million and reaffirming revenue guidance of $118-128 million for the full year. The company highlighted the successful Phase 3 trial of its lead compound, Hydronidone, for treating CHB-associated liver fibrosis, which demonstrated significant fibrosis regression. Leadership changes include the appointment of Ping Zhang as interim CEO following Dr. Han Ying's transition to a scientific leadership role. Additionally, Gyre has successfully launched Etorel in the PRC and is set to conduct further clinical trials in the second half of 2025.
Read more →GYREGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Gyre Therapeutics has successfully dosed the first volunteer in a Phase 1 clinical trial for F230, an ETA receptor antagonist aimed at treating pulmonary arterial hypertension (PAH). This marks Gyre's entry into the PAH field, which is recognized as a rare disease in China. The trial will assess safety and pharmacokinetics in healthy volunteers, expanding Gyre's fibrosis-first strategy.
Read more →GYREGyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gyre Therapeutics has successfully completed a public offering of 2,555,555 shares, raising around $23 million. The offering included the full exercise of an option for additional shares. The funds will be utilized to advance their Phase 2 clinical trial for F351 in treating metabolic dysfunction-associated liver fibrosis. Jefferies and H.C. Wainwright & Co. managed the offering.
Read more →GYREGyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
Gyre Therapeutics has announced the pricing of its public offering of 2,222,222 shares at $9.00 each, aiming to raise about $20 million. The proceeds will be used to advance its Phase 2 clinical trial for F351 targeting liver fibrosis. The offering is expected to close around May 27, 2025, pending customary conditions.
Read more →GYREGyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Gyre Therapeutics has initiated an underwritten public offering of its common stock to fund its Phase 2 clinical trial for liver fibrosis. The offering includes an option for underwriters to purchase additional shares. Proceeds will support research, development, and general corporate purposes. The completion of the offering is subject to market conditions.
Read more →GYREGyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China Achieved statist
Gyre Therapeutics announced that its lead compound, Hydronidone, met the primary endpoint in a pivotal Phase 3 trial focused on liver fibrosis in patients with chronic hepatitis B in China. The trial involved 248 patients and showed statistically significant improvements in fibrosis regression compared to placebo. Gyre plans to submit an NDA to China's NMPA and is preparing for a Phase 2 trial in the U.S. targeting metabolic dysfunction-associated steatohepatitis fibrosis. This development could address a significant unmet need for anti-fibrotic therapies in this population.
Read more →GYREGyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million • Q1 2025 revenue of $22.1 m
Gyre Therapeutics reported its financial results for the first quarter of 2025, achieving a net income of $3.7 million, albeit a decrease compared to the previous year. The company reaffirmed its revenue guidance for the year at $118-$128 million. Key developments include the initiation of commercialization of avatrombopag in China and receiving IND approval for pirfenidone to treat radiation-induced lung injury. Despite a decline in quarterly revenue due to increased competition and reduced sales efforts, Gyre is optimistic about upcoming product launches and market expansion.
Read more →GYRECorporate Presentation April 2025 Developing Anti-Fibrotic Therapeutics for Chronic Organ Diseases Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal secu
Gyre Therapeutics, Inc. presented its forward-looking strategies and development plans for anti-fibrotic therapeutics aimed at chronic organ diseases. The presentation highlights Gyre's promising product pipeline, notably the lead asset F351, designed to address the high unmet need in treating CHB-related liver fibrosis. The company emphasizes its robust commercialization strategy and solid market presence in China, where it has maintained leadership in the fibrosis treatment sector. Gyre also aims to expand its reach with efficient R&D strategies and international clinical trials.
Read more →GYREGyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Gyre Therapeutics announced that the National Medical Products Administration (NMPA) in China has approved their clinical trial application for pirfenidone in treating oncology-related pulmonary complications, specifically focusing on radiation-induced lung injury and immune-related pneumonitis. This development may offer a new treatment option for patients who experience lung damage from radiation or immunotherapy, expanding pirfenidone's use beyond idiopathic pulmonary fibrosis. The company plans to initiate a Phase 2/3 trial in the second half of 2025.
Read more →GYREGyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
Gyre Therapeutics has published the protocol for its Phase 3 clinical trial evaluating F351 for liver fibrosis associated with chronic hepatitis B. The trial involves 248 patients from 44 hospitals in China and aims to assess the efficacy of F351 as a treatment. With Breakthrough Therapy designation already granted, Gyre anticipates topline results in the second quarter of 2025. This research represents a significant advancement for the company in the field of liver fibrosis treatment.
Read more →GYREGyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC
Gyre Therapeutics has reported its fourth quarter and full year financial results for 2024, highlighting key developments and upcoming milestones. The company expects significant revenue growth and product launches in the PRC in 2025, including nintedanib and avatrombopag. Gyre also reported that topline data from its pivotal Phase 3 trial in CHB-associated liver fibrosis is anticipated in the second quarter of 2025, while facing some declines in revenue and adjusted net income during 2024.
Read more →GYREGNI Group Ltd. (2160) FY2024 Consolidated Financial Results The following information was originally prepared and published by GNI Group Ltd. in Japanese as it contains timely disclosure materials to be submitted to the
GNI Group Ltd. (2160) reported its FY2024 consolidated financial results, showing a decrease in revenue and profit compared to the previous fiscal year. Despite challenges such as geopolitical tensions and inflation, the company maintained steady performance with its main product ETUARY and gained manufacturing rights for Nintedanib. Gyre Pharmaceuticals received approval for a new treatment, enhancing its prospects in the rare disease sector. The group's strategic developments, including ongoing clinical trials and potential subsidiary listings, position it for future growth amidst economic uncertainties.
Read more →GYREGyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
Gyre Therapeutics has appointed Ping Zhang as the lead independent director of its Board of Directors. Zhang brings extensive experience in finance and investment, which the company's CEO anticipates will be invaluable for Gyre as it progresses into a critical year. Ying Luo has resigned from the Board to focus on other responsibilities, with Songjiang Ma stepping in as Chairman of Gyre Pharmaceuticals. The company's development initiatives continue to advance, particularly in the area of chronic organ diseases and fibrosis treatments.
Read more →GYREGyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in
Gyre Therapeutics has reported its financial results for the third quarter of 2024, highlighting the successful completion of a pivotal Phase 3 trial for F351 in CHB-associated liver fibrosis. The company expects to report topline results in early 2025 and plans to launch two new treatments in the PRC, including avatrombopag and nintedanib. Despite significant achievements, Gyre faced a decline in revenues and must manage its cash resources prudently to fund future operations. The overall outlook remains positive, with several key developments anticipated in 2025.
Read more →GYREGyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Gyre Therapeutics has announced the completion of the last patient in its pivotal Phase 3 trial evaluating F351 for CHB-associated liver fibrosis in China. The trial included 248 patients and is expected to yield topline data by the first quarter of 2025. The company is also planning to leverage these results to begin a Phase 2 trial in the U.S. for F351 targeting MASH-associated fibrosis. F351 has previously received Breakthrough Therapy designation by China's NMPA.
Read more →GYREGyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Gyre Therapeutics, a biotechnology company based in San Diego, will be presenting an overview at the 8th Annual H.C. Wainwright MASH Investor Conference on October 7, 2024. CEO Han Ying, PhD, will lead the presentation, which will focus on the company's operations and development in chronic organ diseases. The live webcast will be accessible on their website, allowing investors and stakeholders to follow their progress and initiatives.
Read more →GYREGyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Gyre Therapeutics, a biotechnology company focused on chronic organ diseases, announced that its CEO, Han Ying, will present a company overview at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. This event is an opportunity for Gyre to share insights about its development programs, including its lead product F351 for treating NASH-associated fibrosis. Following the live presentation, a webcast replay will be available for those interested.
Read more →GYREGyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, e
Gyre Therapeutics released its financial results for Q2 2024, highlighting significant advancements including NMPA approval for avatrombopag maleate tablets for CLD-associated thrombocytopenia. The company also received IND approval for F230 to treat pulmonary arterial hypertension and expects to submit an IND for F351 later this year. Despite a revenue decline due to normalized anti-fibrosis treatment sales, the company reported solid cash reserves supporting its operations. Upcoming data readouts and clinical trials are also anticipated to bolster its therapeutic portfolio.
Read more →GYREGyre Therapeutics to Present at Sidoti Virtual Investor Conference
Gyre Therapeutics, a commercial-stage biotechnology company, announced that its CEO, Han Ying, will be presenting an overview at the Sidoti August Virtual Investor Conference on August 15, 2024. The presentation is expected to provide insights into the company's clinical development programs, particularly focusing on chronic organ diseases. Following the live session, a webcast replay will be available on Gyre's website. Gyre Therapeutics is known for its work on the F351 treatment for NASH-associated fibrosis.
Read more →GYREGyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Gyre Therapeutics has announced the appointment of Dr. David M. Epstein to its Board of Directors, effective August 6, 2024. Dr. Epstein, who has extensive experience in the biotechnology sector, will also serve on the Audit and Compensation Committees. His background includes leading companies through IPOs and developing therapies for various conditions, which Gyre believes will be instrumental in advancing its pipeline of clinical assets focused on fibrotic diseases.
Read more →GYREGyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Gyre Therapeutics has received approval from China's National Medical Products Administration for its avatrombopag maleate tablets, intended to treat thrombocytopenia associated with chronic liver disease. This approval is viewed as a significant milestone for Gyre as it seeks to establish its presence in the Chinese market and expand its product offerings in rare diseases. The drug, which is also approved in the U.S., provides a crucial treatment option for patients undergoing elective procedures or therapies affected by this condition.
Read more →GYREGyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Therapeutics has announced the publication of a study in the Journal of Gastroenterology and Hepatology showcasing hydronidone's effects on liver fibrosis. The study indicates that hydronidone induces apoptosis in activated hepatic stellate cells, potentially aiding in liver fibrosis treatment. The company plans to assess hydronidone in a Phase 3 trial targeting Chronic Hepatitis B-associated liver fibrosis, with results expected by early 2025. Following this, a Phase 2a trial for NASH-associated liver fibrosis is anticipated in 2025.
Read more →GYREGyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension SAN DIEGO, May 30 , 2024 (GLOBE NEWSWIRE) - Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), a
Gyre Pharmaceuticals has received Investigational New Drug (IND) approval from China's NMPA to evaluate its F230 tablets for the treatment of pulmonary arterial hypertension (PAH). The approval allows Gyre to advance clinical trials for F230, a selective endothelin receptor antagonist. In preclinical studies, F230 demonstrated significant reductions in pulmonary arterial pressure and other key metrics. The company is also exploring additional disease indications for F230, highlighting their commitment to addressing unmet medical needs in rare diseases.
Read more →GYREGyre Therapeutics Announces Expected Addition to the Russell 2000 and Russell 3000 Indexes
Gyre Therapeutics announced its expected inclusion in the Russell 2000 and 3000 Indexes, set to take effect after market close on June 28, 2024. This addition marks a key milestone for the company and reflects its growth as a clinical-stage biotechnology firm developing anti-fibrotic therapeutics. CEO Han Ying highlighted the potential for increased visibility and value for stockholders as the company continues to advance its lead product, F351, in the U.S. and China. The Russell Indexes are considered important benchmarks in asset management, indicating a robust market presence for Gyre.
Read more →GYREGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data
Gyre Therapeutics reported its financial results for the first quarter of 2024, showing a net income of $9.9 million, a significant increase from $4.2 million in the same period last year. The company is progressing with its Phase 3 clinical trial for F351, targeting CHB-associated liver fibrosis, with topline data expected by early 2025. Additionally, Gyre plans to submit an IND for a Phase 2a trial for NASH-associated liver fibrosis by late 2024. Despite a reduction in cash reserves compared to the previous quarter, the company reported strong sales from its drug ETUARY.
Read more →GYRENotification of Conclusion of License Agreement by Gyre Pharmaceuticals Co. GNI Group ("the Company") is pleased to announce that Gyre Pharmaceuticals Co. Ltd., aka Beijing Continent Pharmaceuticals Co., Ltd. ("BC"), a c
Gyre Pharmaceuticals Co. Ltd., a subsidiary of GNI Group, has signed a license agreement with Jiangsu Wangao Pharmaceuticals to acquire rights to generic Nintedanib, targeting the idiopathic pulmonary fibrosis (IPF) market. With ETUARY already showing strong annual sales growth, the move aims to expand Gyre's product lineup within the fibrosis treatment space. The IPF drug market in China is projected to grow significantly, suggesting potential revenue increases. However, the company notes that its current capacity struggles to keep up with market demand, which is a concern.
Read more →GYREGyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Data readout from Phase 3 clinical trial in the People's Republic of China ( “ PRC ”) evaluating F351 for the treatmen
Gyre Therapeutics reported its financial results for the full year 2023, highlighting a successful year with revenue growth. The company anticipates data readouts from its Phase 3 trial for F351 in China by early 2025 and plans to initiate a Phase 2a trial for NASH-associated liver fibrosis in the U.S. in 2025. Gyre also appointed Dr. Han Ying as CEO and reported strong sales figures for its existing product, ETUARY, which saw a 13% increase in 2023. The company ended the year with $33.5 million in cash reserves.
Read more →GYREGyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Gyre Therapeutics has appointed Rodney L. Nussbaum to its Board of Directors, bringing nearly four decades of experience in finance and auditing. Nussbaum is expected to leverage his expertise to enhance Gyre's commercial growth, particularly in increasing sales in China and advancing product candidates through clinical development. The appointment comes at a pivotal time for Gyre as it continues to develop its anti-fibrotic therapies. Gyre is making strides with its lead candidate, Hydronidone (F351), which has received Breakthrough Therapy designation in China.
Read more →GYREThe following information was originally prepared and published by GNI Group Ltd. in Japanese as it contains timely disclosure materials to be submitted to the Tokyo Stock Exchange. This English summary translation is fo
GNI Group Ltd. reported robust financial results for FY2023, achieving record revenue and profit due to strong sales, particularly from its subsidiary Beijing Continent Pharmaceutical Co., Ltd. The company has also accelerated the Phase III clinical trial of its product F351 ahead of schedule. Furthermore, it successfully partnered with Catalyst Biosciences, now known as Gyre Therapeutics, to advance clinical trials in the U.S. The company anticipates continued growth and has forecasted further increases for FY2024.
Read more →GYREQuarterly Report (3Q of 23rd Fiscal Period)
GNI Group Ltd. reported substantial growth in its 3Q financial results for the fiscal period ending September 30, 2023, showcasing significant revenue increases driven by strong sales of its flagship product, ETUARY. The company is advancing its clinical trials for F351, with expectations for patient enrollment completion by year-end. Furthermore, the completion of a transaction with Catalyst Biosciences to transfer F351's non-Chinese rights and plans to establish new business ventures in the United States indicate robust strategic positioning. Financial metrics demonstrated improvement across various indicators, reflecting a recovery trend in Japan's economy amid ongoing global uncertainties.
Read more →GYREGyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
Gyre Therapeutics announced the presentation of a poster at the AASLD Annual Liver Meeting regarding their lead asset, Hydronidone. The poster outlined the drug's potential antifibrotic effects and mechanistic data gathered from mouse fibrosis models. The CEO expressed optimism about Hydronidone's efficacy, stating it may help treat liver fibrosis. The company is set to start a clinical program for Hydronidone in the United States in 2024.
Read more →GYRECATALYST
Catalyst Biosciences has announced the completion of its business combination with Beijing Continent Pharmaceuticals, with the new company now named Gyre Therapeutics, Inc. This transition includes a reverse stock split as the combined entity starts trading on Nasdaq under the ticker GYRE from October 31, 2023. Gyre plans to enhance clinical research in fields including organ fibrosis and inflammatory diseases, though potential risks remain regarding the realization of expected benefits and variability in clinical outcomes.
Read more →GYREBEIJING CONTINENT PHARMACEUTICALS CO., LTD. Pages UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited interim condensed consolidated statements of profit or loss and other comprehensive income for the
Beijing Continent Pharmaceuticals Co., Ltd. reported unaudited interim financial results for the first half of 2023, highlighting a notable increase in revenue and net profit compared to the same period in 2022. Revenue rose to 379,265 RMB, while net profit reached 81,198 RMB. Additionally, the company's total assets grew to 806,617 RMB, reflecting a strong financial position. The report indicates ongoing positive performance trends within the company.
Read more →GYRECatalyst Biosciences Corporate Presentation 20 March 2023 2 Catalyst Biosciences Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the fede
Catalyst Biosciences has presented forward-looking statements regarding its strategic direction, focusing on the development of Hydronidone (F351) for treating liver fibrosis and NASH. The company plans to finalize a business combination with Beijing Continent, a Chinese biopharmaceutical entity, in mid-2023. While Hydronidone demonstrates a promising safety and efficacy profile, risks remain regarding both its clinical development and the timely completion of the partnership. Cash distributions to contingent value rights holders are planned for 2023 and 2025, along with further clinical data expected in 2024.
Read more →GYRECatalyst Biosciences Provides Corporate Update
Catalyst Biosciences announced a corporate update, focusing on its recent acquisition of the small molecule F351 to treat fibrotic diseases. The company is transitioning away from its previous focus on protease engineering, aiming to provide distributions to stockholders through asset monetization. However, the management outlined various risks and uncertainties that could impact future transactions and expected financial performance.
Read more →GYRECatalyst Biosciences Completes First Steps in Reverse Merger Plan Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Grou
Catalyst Biosciences Completes First Steps in Reverse Merger Plan Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 million Specia
Read more →GYREPRIVILEGED AND CONFIDENTIAL PREPARED AT THE DIRECTION OF COUNSEL Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
PRIVILEGED AND CONFIDENTIAL PREPARED AT THE DIRECTION OF COUNSEL Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share SOUTH SAN FRANCISCO, Calif., August 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) ("Catalyst," the "Company" o
Read more →GYREEXECUTION VERSION Cooperation Agreement This Cooperation Agreement (this " Agreement ") is made and entered into as of
Cooperation Agreement This Cooperation Agreement (this "Agreement") is made and entered into as of August 18, 2022 (the "Effective Date") by and among Catalyst Biosciences, Inc., a Delaware corporation (the "Company"), and each of the parties listed on Exhibit A hereto (each, a
Read more →GYRECatalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results
Catalyst Biosciences Reports Second Quarter 2022 Operating & Financial Results SOUTH SAN FRANCISCO, Calif. - Aug. 15, 2022 - Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the "Company" or "we") today announced its operating and financial results for the second quarter ended June 30
Read more →GYREExecution Version Confidential Agreement This agreement (the " Agreement ") is made and entered into as of
This agreement (the "Agreement") is made and entered into as of July 31, 2022 (the "Effective Date") by and among Catalyst Biosciences, Inc., a Delaware corporation (the "Company"), and each of the parties listed on Exhibit A hereto (each, an "Investor" and collectively, the "I
Read more →GYRECERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH [***]. A
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH [***]. ASSET PURCHASE AGREEMENT CATALYST BIOSCIENCES, INC. VER
Read more →GYRECatalyst Biosciences Sells Complement Portfolio for $60 Million
Catalyst Biosciences Sells Complement Portfolio for $60 Million SOUTH SAN FRANCISCO, Calif. May 23, 2022 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ:
Read more →GYRECatalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results SOUTH SAN FRANCISCO, Calif. May 9, 2022 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. In the first quarter,
Read more →GYRECatalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update SOUTH SAN FRANCISCO, Calif. March 31, 2022 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth
Read more →GYRECatalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI SOUTH SAN FRANCISCO, Calif. January 25, 2022 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Di
Read more →GYRECatalyst Biosciences Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and
CATALYST BIOSCIENCES Corporate Overview 12 January 2022 Exhibit 99.1 Catalyst Biosciences Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substanti
Read more →GYRECatalyst Biosciences Announces Change in Corporate Strategy Reports Third Quarter 2021 Operating & Financial Results Company to discontinue MarzAA development; focus on developing its complement portfolio Management to h
Catalyst Biosciences Announces Change in Corporate Strategy Reports Third Quarter 2021 Operating & Financial Results Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Cali
Read more →GYRECatalyst Biosciences Announces Chief Financial Officer Transition
Catalyst Biosciences Announces Chief Financial Officer Transition SOUTH SAN FRANCISCO, Calif. October 13, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal reasons effective October 29, 2021
Read more →GYREFDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency SOUTH SAN FRANCISCO, Calif. September 28, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted O
Read more →GYREForward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All s
CATALYST BIOSCIENCES Corporate Overview 28 September 2021 Exhibit 99.1 Forward looking statements Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncert
Read more →GYRECatalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise
Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise SOUTH SAN FRANCISCO, Calif. September 8, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the
Read more →GYRENasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 7 September 2021 CatalystBiosciences.com Forward looking statements Certain information contained in this presentation and statements made orally during this presentat
September 2021 CatalystBiosciences.comExhibit 99.1 Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 7 September 2021 CatalystBiosciences.com Forward looking statements Certain information contained in this presentation and statements made orally during this presentation inc
Read more →GYRECatalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a SOUTH SAN FRANCISCO, Calif. August 5, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, and
Read more →GYRECatalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies Launching the C on FI rm study to identify patients with Complement Factor I defici
Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies Launching the ConFIrm study to identify patients with Complement Factor I deficiencies SOUTH SAN FRANCISCO, Calif. July 22, 2021 Catalyst Bi
Read more →GYRENasdaq: CBIO HARNESSING THE CATALYTIC POWER OF PROTEASES Complement R&D Day 19 July 2021 CatalystBiosciences.com Forward-looking statements Certain information contained in this presentation and statements made orally du
Complement R&D Day 19 July 2021 CatalystBiosciences.comExhibit 99.1 Nasdaq: CBIO HARNESSING THE CATALYTIC POWER OF PROTEASES Complement R&D Day 19 July 2021 CatalystBiosciences.com Forward-looking statements Certain information contained in this presentation and statements made
Read more →GYRETarget the complement cascade to maximize the success of your ARDS therapeutic Catalyst Biosciences ARDS: unmet need after half a century of research Complement involvement in ARDS Challenges in developing complement the
Catalyst Biosciences Catalyst Biosciences ARDS summit, July 13th 2021 Complement System in ARDS Natacha Le Moan Exhibit 99.1 Target the complement cascade to maximize the success of your ARDS therapeutic Catalyst Biosciences ARDS: unmet need after half a century of research Co
Read more →GYRECatalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency Second Fast Track Designation for MarzAA
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency Second Fast Track Designation for MarzAA SOUTH SAN FRANCISCO, Calif. June 28, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today a
Read more →GYRECatalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra
Catalyst Biosciences Announces First Patient Dosed in Marzeptacog Alfa (Activated) Phase 1/2 Study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra SOUTH SAN FRANCISCO, Calif. May 18, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today
Read more →GYRECatalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports First Quarter 2021 Operating & Financial Results and Provides a SOUTH SAN FRANCISCO, Calif. May 6, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and prov
Read more →GYRECatalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors
Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors SOUTH SAN FRANCISCO, Calif. May 5, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first
Read more →GYRECatalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update SOUTH SAN FRANCISCO, Calif. March 4, 2021 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth q
Read more →GYRECatalyst Biosciences Announces Pricing of Public Offering of Common Stock
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., January 27, 2021 Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the Company ) today announced the pricing of an underwritten public offering of 8,700,000 shares of its common stock
Read more →GYRECatalyst Biosciences Announces Proposed Public Offering of Common Stock
Catalyst Biosciences Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., January 26, 2021-- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is s
Read more →GYRECatalyst Biosciences Overview & KOL introduction Catalyst's complement program Virtual complement R&D day agenda 12:00 pm - 12:10 pm ET Nassim Usman, Ph.D. - President and CEO Company vision Protease engineering platform
Catalyst Biosciences Catalyst Biosciences Complement R&D Day 14 December 2020 Exhibit 99.1 Catalyst Biosciences Overview & KOL introduction Catalyst's complement program Virtual complement R&D day agenda 12:00 pm - 12:10 pm ET Nassim Usman, Ph.D. - President and CEO Company vi
Read more →GYRECatalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors SOUTH SAN FRANCISCO, Calif. Dec. 2, 2020 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug
Read more →GYRENasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 17 November 2020 CatalystBiosciences.com Catalyst Biosciences Forward looking statements This presentation includes forward-looking statements that involve Various imp
November 2020 CatalystBiosciences.com Catalyst BiosciencesExhibit 99.1 Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 17 November 2020 CatalystBiosciences.com Catalyst Biosciences Forward looking statements This presentation includes forward-looking statements that involv
Read more →GYRECatalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update SOUTH SAN FRANCISCO, Calif. Nov. 5, 2020 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended Septe
Read more →GYRENasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 17 September 2020 CatalystBiosciences.com Catalyst Biosciences Forward looking statements This presentation includes forward-looking statements that involve substantia
Nasdaq: CBIO CATALYST BIOSCIENCES Corporate Overview 17 September 2020 CatalystBiosciences.com Catalyst Biosciences Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties All statements included in this
Read more →GYRECatalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update SOUTH SAN FRANCISCO, Calif. August 6, 2020 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended J
Read more →GYRECATALYST BIOSCIENCES Corporate Overview 18 June 2020 1 Nasdaq: CBIO Forward looking statements Various important factors could cause actual results or events to differ This presentation includes forward-looking statement
1Exhibit 99.1 CATALYST BIOSCIENCES Corporate Overview 18 June 2020 1 Nasdaq: CBIO Forward looking statements Various important factors could cause actual results or events to differ This presentation includes forward-looking statements that involve materially, including, but no
Read more →GYRECatalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer SOUTH SAN FRANCISCO, Calif. June 15, 2020 Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Clinton Musil as its new chief financial officer, effective July 1, 2020. Mr. Musil br
Read more →GYRECatalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedba
Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presen
Read more →GYRECatalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement w
Read more →GYRECATALYST BIOSCIENCES Corporate Overview 7 February 2020 Forward looking statements Nasdaq: CBIO This presentation includes forward-looking statements Various important factors could cause actual results or that involve s
CATALYST BIOSCIENCES Corporate Overview 7 February 2020 Forward looking statements Nasdaq: CBIO This presentation includes forward-looking statements Various important factors could cause actual results or that involve substantial risks and uncertainties All events to differ ma
Read more →GYRECatalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors SOUTH SAN FRANCISCO, Calif., Jan.17, 2020 Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopha
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors FRANCISCO, Calif., Jan.17, 2020 Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and o
Read more →GYREForward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statement of historical facts, a
CATALYST BIOSCIENCES Corporate Overview 8 January 2020 Exhibit 99.1 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statement of historic
Read more →GYRECatalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration Catalyst to receive $15 million upfront and is eligible to
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration Catalyst to receive $15 million upfront and is eligible to receive an additional $340 million in milestones and tier
Read more →GYRECatalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update FRANCISCO, Calif. November 7, 2019 Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 3
Read more →GYRECatalyst Biosciences Provides DalcA Phase 2b Trial Update Two subjects have successfully completed dosing, exceeded the FIX activity efficacy endpoint and no anti-drug antibodies were detected
Catalyst Biosciences Provides DalcA Phase 2b Trial Update Two subjects have successfully completed dosing, exceeded the FIX activity efficacy endpoint and no anti-drug antibodies were detected SOUTH SAN FRANCISCO, Calif. October 3, 2019 Catalyst Biosciences, Inc. (NASDAQ: CBIO
Read more →GYRECatalyst Biosciences Announces Transition of Chief Financial Officer
Catalyst Biosciences Announces Transition of Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to pursue another
Read more →GYRECatalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rat
Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with >90% r
Read more →GYRECatalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH)
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation rec
Read more →GYRECatalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated) Dosing successfully completed in the Phase 2 portion of the Phase 2/3 MarzAA trial for the treatment of hemop
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated) Dosing successfully completed in the Phase 2 portion of the Phase 2/3 MarzAA trial for the treatment of hemophilia A or B with inhibitors SOUTH SAN FRANCISCO, Calif.
Read more →GYRECatalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical effica
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with >90% reduction in bleeding Completed a full imm
Read more →GYREForward looking statements 1 & 2 October 2018 Nassim Usman, Ph.D. President & CEO This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than stateme
CATALYST BIOSCIENCES December 18th 2018 Research & Development Day Exhibit 99.1 Forward looking statements 1 & 2 October 2018 Nassim Usman, Ph.D. President & CEO This presentation includes forward-looking statements that involve substantial risks and uncertainties. All stateme
Read more →GYRECatalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVII
Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Presented Updated Positive Interim Data from the Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) at Two Scientific Published Data from Phase 1 Study of Marzeptacog Alfa (Ac
Read more →GYRECatalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit Data demonstrates continued efficacy of marzeptacog alfa (activated) in two additional subjects
Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit Data demonstrates continued efficacy of marzeptacog alfa (activated) in two additional subjects SOUTH SAN FRANCISCO, Calif. Aug. 15, 2018 Catalyst Biosciences, Inc. (NAS
Read more →GYRECatalyst Biosciences Reports Second Quarter Operating & Financial Results and Provides Corporate Update Announced Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) in Indiv
Catalyst Biosciences Reports Second Quarter Operating & Financial Results and Provides Corporate Announced Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) (FVIIa) in Individuals with Hemophilia A or B with Inhibitors Presented CB 2679d (FIX) Phase
Read more →GYRECatalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors Interim data support goal of significantly reducing annual
Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors Interim data support goal of significantly reducing annualized bleed rates with daily subcutaneous injections of ma
Read more →GYREForward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this presentation a
21 June 2018 Catalyst Biosciences Essential Medicines for Hemophilia Greater Convenience Superior Outcomes Exhibit 99.1 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than
Read more →GYRECatalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B Conference call and webcast to be held today
Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B Conference call and webcast to be held today, June 18, 2018 at 8:30 a.m. EDT SOUTH SAN FRANCISCO, Calif. June 18, 2018 Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage
Read more →GYRECatalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update Announced Korean Ministry of Food and Drug Safety approval to add sixth cohort to the Phase 1/2 trial of
Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Announced Korean Ministry of Food and Drug Safety approval to add sixth cohort to the Phase 1/2 trial of CB 2679d/ISU304 in individuals with hemophilia B Raised approximately $106.8
Read more →GYRECatalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B Initiation of Phase 2b Trial on Track fo
Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B Initiation of Phase 2b Trial on Track for Q3 2018 SOUTH SAN FRANCISCO, Calif. April 12, 2018 Cata
Read more →GYRECatalyst Biosciences Announces the Calling of Remaining Warrants and Conversion of Remaining Series A Preferred Shares Issued
Catalyst Biosciences Announces the Calling of Remaining Warrants and Conversion of Remaining Series A Preferred Shares Issued April 12, 2017 Total of 11.9 million common shares outstanding post-conversion and warrant exercise SOUTH SAN FRANCISCO, Calif. Mar. 5, 2018 Catalyst B
Read more →GYRECatalyst Biosciences, Inc. Consolidated Statements of Operations (In thousands, except shares and per share amounts) Year Ended
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results and Provides Corporate Update Cash Balance in excess of $135 million after our February 2018 follow-on financing allows for independent development of lead programs Positive Phase 1/2 S
Read more →GYREForward Looking Statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this presentation a
Catalyst Biosciences 12 February 2018 Essential Medicines for Hemophilia Greater Convenience Superior Outcomes Nasdaq: CBIO Exhibit 99.1 Forward Looking Statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All state
Read more →GYRECatalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B All individuals with severe hemophilia improved to mild hemophilia activity leve
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear in
Read more →GYRECatalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors Currently Enrolling Individuals with Hemophilia A or B with Inhibitors Interim Data Expe
Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors Currently Enrolling Individuals with Hemophilia A or B with Inhibitors Interim Data Expected During the First Half of 2018 SOUTH SAN FRANCISCO,
Read more →GYRECatalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Sub
Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B Korean Ministry of Food and Drug Safety Approves Omitting Cohort 4 and Dosing Cohort 5 with Six Daily Subcutaneous Doses of Next-Generation Coagulation Factor IX C
Read more →GYREPhase1/2 Trial of Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics and Activity Chur Woo You, MD PhD, Ho-Jin Shin, MD, Howard Levy MBBCh PhD, Martin Lee, PhD, Seung-Beom Hong, PhD, Jamie El
Phase1/2 Trial of Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics and Activity Chur Woo You, MD PhD, Ho-Jin Shin, MD, Howard Levy MBBCh PhD, Martin Lee, PhD, Seung-Beom Hong, PhD, Jamie Ellen Siegel, MD and June Young Park, MD 87 Session 322. Disor
Read more →GYRECatalyst Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended
Exhibit 99.1 NEWS RELEASE Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update -- Phase 1/2 trial of Factor IX CB 2679d is advancing with interim results expected by year-end - -- Phase 2 trial of Factor FVIIa marzeptacog
Read more →GYRECatalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors Senior pharmaceutical executive with extensive experience in hematology and hemophilia Led Baxalta s Global Blood D
Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors Senior pharmaceutical executive with extensive experience in hematology and hemophilia Led Baxalta s Global Blood Disorders Franchise within the Hematology Division SOUTH
Read more →GYRECatalyst Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended
Catalyst Biosciences Reports Second Quarter 2017 Financial Results and Provides Subcutaneous (SQ) Hemophilia Program Update -- Enrollment into Phase 1/2 trial of Factor IX SQ candidate CB 2679d is ongoing; trial is on track to announce interim results by year-end -- -- Raised $
Read more →GYRECatalyst Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended
Exhibit 99.1 NEWS RELEASE Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update -- Raised ~$20 million through an underwritten equity offering -- -- Factor IX Hemophilia B program milestone payment received after completion of IND-
Read more →GYRECatalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering SOUTH SAN FRANCISCO, Calif., April 07, 2017 (GLOBE NEWSWIRE) Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address
Read more →GYRECatalyst Biosciences Announces 1-for-15 Reverse Stock Split
Catalyst Biosciences Announces 1-for-15 Reverse Stock Split SOUTH SAN FRANCISCO, Calif., February 10, 2017 Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced a reverse s
Read more →GYRER&R PRESENTATION SEPT 13, 2016 cbio-ex991_22.pptx.htm Catalyst Biosciences Non-Confidential Company Update 12 September 2016 Essential Medicines for Hemophilia. Greater Convenience. Superior Outcomes Forward Looking Stat
Catalyst Biosciences Non-Confidential Company Update 12 September 2016 Essential Medicines for Hemophilia. Greater Convenience. Superior Outcomes Forward Looking Statements This presentation includes forward-looking statements relating to the Catalyst Biosciences, Inc. (the "Com
Read more →GYREintentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements t
Catalyst Biosciences to Focus Resources on Clinical Hemostasis Programs Company to Focus on Improved Factor VIIa and IX Programs to Provide Prophylactic Subcutaneous Therapy to Hemophilia Patients Reduction in Workforce will Reallocate Financial Resources from Research Progr
Read more →GYRECatalyst Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update Phase 1 Proof-of-Concept Clinical Trial of High Potency Factor IX Product Subcutaneous Administration for Hemo
Catalyst Biosciences Reports Second Quarter 2016 Financial Results and Provides Corporate Update Phase 1 Proof-of-Concept Clinical Trial of High Potency Factor IX Product Subcutaneous Administration for Hemophilia B to Commence in the First Quarter 2017 Manufacturing Agreement
Read more →GYRECatalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst s Next-Generation Factor VIIa Product CB 813d - Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Fact
Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst s Next-Generation Factor VIIa Product CB 813d - Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor VIIa CB 813d - - Catalyst Plans to Initiate Clinical Pi
Read more →GYRECatalyst Biosciences Announces Appointments of Chief Medical Officer and Vice President of Business Development Dr. Howard Levy Appointed Chief Medical Officer; Deep Experience in Hematology Drug Development
Catalyst Biosciences Announces Appointments of Chief Medical Officer and Vice President of Business Development Dr. Howard Levy Appointed Chief Medical Officer; Deep Experience in Hematology Drug Development and Medicine Jeffrey Landau, Accomplished Corporate Development and
Read more →GYRECatalyst Biosciences Exceptional Science. Essential Medicines. Company Overview December 2015 1 Forward Looking Statements This presentation includes forward-looking statements relating to the Catalyst Biosciences, Inc.
Catalyst Biosciences Exceptional Science. Essential Medicines. Company Overview December 2015 Forward Looking Statements includes forward-looking statements relating to the Catalyst Biosciences, Inc. (the Company ). Forward-looking statements include statements about the pote
Read more →GYRECatalyst Biosciences Names Andrew Hetherington as Vice President of Manufacturing Operations Seasoned manufacturing operations executive from Novartis and Bayer to spearhead Catalyst s manufacturing capabilities South Sa
Catalyst Biosciences Names Andrew Hetherington as Vice President of Manufacturing Operations Seasoned manufacturing operations executive from Novartis and Bayer to spearhead Catalyst s manufacturing capabilities South San Francisco, Calif. Sept. 28, 2015 Catalyst Biosciences, I
Read more →GYRECatalyst Biosciences Completes Merger with Targacept and Creates a Protease-Based Hemostasis and Anti-Complement Company - Newly NASDAQ-listed CBIO focused on development of next-generation and long-acting coagulation fa
Catalyst Biosciences Completes Merger with Targacept and Creates a Protease-Based Hemostasis and Anti-Complement Company - Newly NASDAQ-listed CBIO focused on development of next-generation and long-acting coagulation factors and novel proteases that target the complement path
Read more →GYRETargacept Announces Stockholder Approval of Proposals Related to Merger with Catalyst Biosciences
Targacept Announces Stockholder Approval of Proposals Related to Merger with Catalyst Biosciences August 18, 2015 Winston-Salem, NC- Targacept, Inc. (NASDAQ: TRGT) today announced that its stockholders have voted to approve the adoption of the agreement and plan of merger, date
Read more →GYRETargacept Declares Pre-closing Dividend in Connection with its Merger with Catalyst Biosciences, Inc. Winston-Salem, NC
Targacept Declares Pre-closing Dividend in Connection with its Merger with Catalyst Biosciences, Inc. Winston-Salem, NC August 4, 2015 Targacept, Inc. (NASDAQ: TRGT) announced today that its board of directors has declared a pre-closing dividend, in connection with its merger w
Read more →GYRETargacept and Catalyst Biosciences Amend Definitive Merger Agreement Winston-Salem, NC and South San Francisco, CA
Targacept and Catalyst Biosciences Amend Definitive Merger Agreement Winston-Salem, NC and South San Francisco, CA May 14, 2015 Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced that they have entered in
Read more →GYRETargacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis Winston-Salem, NC
Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic Gastroparesis Winston-Salem, NC April 16, 2015 Targacept, Inc. (NASDAQ: TRGT) today announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic g
Read more →GYRETHOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT TRGT Targacept Inc and Catalyst Biosciences Enter Definitive Merger Agreement EVENT DATE/TIME: MARCH 06, 2015 / 01:30PM GMT CORPORATE PARTICIPANTS Stephen Hill Targacept, In
THOMSON REUTERS STREETEVENTS TRGT Targacept Inc and Catalyst Biosciences Enter Definitive Merger Agreement EVENT DATE/TIME: MARCH 06, 2015 / 01:30PM GMT CORPORATE PARTICIPANTS Stephen Hill Targacept, Inc. President and CEO Nassim Usman Catalyst Biosciences CEO CONFERENCE C
Read more →GYRETargacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company Merger combines Catalyst s protease therapeutics pipeline and the financial resources
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company Merger combines Catalyst s protease therapeutics pipeline and the financial resources of both companies Creates a well-funded company to develop
Read more →GYRETargacept Reports Third Quarter 2014 Financial Results Winston-Salem, North Carolina
Targacept Reports Third Quarter 2014 Financial Results Winston-Salem, North Carolina, November 5, 2014 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics , today reported its financial results for the third quarter and nine mon
Read more →GYRETargacept Reports Second Quarter 2014 Financial Results Winston-Salem, North Carolina
Targacept Reports Second Quarter 2014 Financial Results Winston-Salem, North Carolina, August 6, 2014 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics , today reported its financial results for the second quarter and six mont
Read more →GYRETargacept to Discontinue TC-5214 Overactive Bladder Program Winston-Salem, NC
Targacept to Discontinue TC-5214 Overactive Bladder Program Winston-Salem, NC July 28, 2014 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics , today announced top-line results from a Phase 2b clinical trial of TC-5214 as a tr
Read more →GYRETargacept Phase 2b Clinical Trial in Alzheimer s Disease Does Not Show Superiority of TC-1734 Over Donepezil Winston-Salem, NC
Targacept Phase 2b Clinical Trial in Alzheimer s Disease Does Not Show Superiority of TC-1734 Over Donepezil Winston-Salem, NC July 14, 2014 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today announced top-line r
Read more →GYRETargacept Reports First Quarter 2014 Financial Results Winston-Salem, North Carolina
Targacept Reports First Quarter 2014 Financial Results Winston-Salem, North Carolina, May 7, 2014 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today reported its financial results for the first quarter ended Marc
Read more →GYRETargacept Reports Fourth Quarter and 2013 Financial Results Winston-Salem, North Carolina
Targacept Reports Fourth Quarter and 2013 Financial Results Winston-Salem, North Carolina, February 13, 2014 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today reported its financial results for the fourth quarte
Read more →GYRETargacept Announces Negative Top-Line Results from Phase 2b Clinical Trial of TC-5619 in Schizophrenia Targacept to Host Conference Call to Discuss Results on Tuesday, December 17 at 8:45 a.m. Winston-Salem, NC
Targacept Announces Negative Top-Line Results from Phase 2b Clinical Trial of TC-5619 in Schizophrenia Targacept to Host Conference Call to Discuss Results on Tuesday, December 17 at 8:45 a.m. Winston-Salem, NC December 16, 2013 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage
Read more →GYRETargacept Reports Third Quarter 2013 Financial Results Winston-Salem, North Carolina
Targacept Reports Third Quarter 2013 Financial Results Winston-Salem, North Carolina, November 5, 2013 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today reported its financial results for the third quarter and n
Read more →GYRETargacept Reports Second Quarter 2013 Financial Results Winston-Salem, North Carolina
Targacept Reports Second Quarter 2013 Financial Results Winston-Salem, North Carolina, August 6, 2013 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today reported its financial results for the second quarter and s
Read more →GYRETargacept Reports First Quarter 2013 Financial Results Winston-Salem, North Carolina
Targacept Reports First Quarter 2013 Financial Results Winston-Salem, North Carolina, May 7, 2013 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics , today reported its financial results for the first quarter ended Marc
Read more →Competitive Position
How GYRE ranks across every disease it competes inCompetitive Position is a premium feature
See how GYRE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial